CL2020002805A1 - Método para identificar un modulador de un sistema biológico; método para identificar un modulador de un proceso de enfermedad (divisional 201302526) - Google Patents

Método para identificar un modulador de un sistema biológico; método para identificar un modulador de un proceso de enfermedad (divisional 201302526)

Info

Publication number
CL2020002805A1
CL2020002805A1 CL2020002805A CL2020002805A CL2020002805A1 CL 2020002805 A1 CL2020002805 A1 CL 2020002805A1 CL 2020002805 A CL2020002805 A CL 2020002805A CL 2020002805 A CL2020002805 A CL 2020002805A CL 2020002805 A1 CL2020002805 A1 CL 2020002805A1
Authority
CL
Chile
Prior art keywords
modulator
identify
biological system
divisional
disease process
Prior art date
Application number
CL2020002805A
Other languages
English (en)
Inventor
Niven Rajin Narain
Rangaprasad Sarangarajan
Vivek K Vishnudas
Original Assignee
Berg Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berg Llc filed Critical Berg Llc
Publication of CL2020002805A1 publication Critical patent/CL2020002805A1/es

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G16B5/20—Probabilistic models
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Genetics & Genomics (AREA)
  • Probability & Statistics with Applications (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Mobile Radio Communication Systems (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)

Abstract

Un método para proporcionar un modelo para un sistema biológico para su uso en un método de plataforma, que comprende: establecer un modelo para un sistema biológico, usando células asociadas con el sistema biológico, para representar un aspecto característico del sistema biológico, donde el modelo para el sistema biológico es útil para generar conjuntos de datos usados en el método de plataforma; proporcionando así un modelo para un sistema biológico para uso en un método de plataforma.
CL2020002805A 2011-03-02 2020-10-28 Método para identificar un modulador de un sistema biológico; método para identificar un modulador de un proceso de enfermedad (divisional 201302526) CL2020002805A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161448587P 2011-03-02 2011-03-02
US201261593848P 2012-02-01 2012-02-01

Publications (1)

Publication Number Publication Date
CL2020002805A1 true CL2020002805A1 (es) 2021-04-30

Family

ID=46758320

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2013002526A CL2013002526A1 (es) 2011-03-02 2013-09-02 Método para identificar un modulador de un sistema biológico; método para identificar un modulador de un proceso de enfermedad.
CL2020002805A CL2020002805A1 (es) 2011-03-02 2020-10-28 Método para identificar un modulador de un sistema biológico; método para identificar un modulador de un proceso de enfermedad (divisional 201302526)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2013002526A CL2013002526A1 (es) 2011-03-02 2013-09-02 Método para identificar un modulador de un sistema biológico; método para identificar un modulador de un proceso de enfermedad.

Country Status (20)

Country Link
US (3) US9886545B2 (es)
EP (1) EP2680925B1 (es)
JP (2) JP6105491B2 (es)
KR (1) KR102071081B1 (es)
CN (2) CN107273712B (es)
AU (2) AU2012223136B2 (es)
BR (1) BR112013022208A2 (es)
CA (1) CA2828972C (es)
CL (2) CL2013002526A1 (es)
CO (1) CO6801640A2 (es)
EA (1) EA201391245A1 (es)
ES (1) ES2777894T3 (es)
IL (2) IL228096B (es)
MX (1) MX358408B (es)
MY (2) MY164530A (es)
PE (2) PE20180776A1 (es)
PH (2) PH12017502072A1 (es)
SG (2) SG193006A1 (es)
WO (1) WO2012119129A1 (es)
ZA (1) ZA201306453B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120077206A1 (en) 2003-07-12 2012-03-29 Accelr8 Technology Corporation Rapid Microbial Detection and Antimicrobial Susceptibility Testing
WO2005027714A2 (en) 2003-07-12 2005-03-31 Accelr8 Technology Corporation Sensitive and rapid biodetection
US10254204B2 (en) 2011-03-07 2019-04-09 Accelerate Diagnostics, Inc. Membrane-assisted purification
ES2551922T3 (es) 2011-03-07 2015-11-24 Accelerate Diagnostics, Inc. Sistemas rápidos de purificación celular
US20150023949A1 (en) * 2012-03-05 2015-01-22 Berg Llc Compositions and methods for diagnosis and treatment of pervasive developmental disorder
US9744155B2 (en) 2012-03-28 2017-08-29 Ixcela, Inc. IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk
AU2012376214B2 (en) * 2012-04-02 2019-02-14 Berg Llc Interrogatory cell-based assays and uses thereof
MX2014013875A (es) 2012-05-22 2015-06-04 Berg Llc Ensayo basado en celulas interrogadoras para identificar marcadores de toxicidad inducida por medicamentos.
WO2014071316A1 (en) * 2012-11-02 2014-05-08 H. Lee Moffitt Cancer Center And Research Institute, Inc. In silico identification of cancer molecular signaling pathways and drug candidates
US20150302167A1 (en) * 2012-11-09 2015-10-22 Cellworks Group, Inc. System and method for development of therapeutic solutions
US9677109B2 (en) 2013-03-15 2017-06-13 Accelerate Diagnostics, Inc. Rapid determination of microbial growth and antimicrobial susceptibility
JP6216044B2 (ja) * 2013-05-28 2017-10-18 ファイヴ３ ゲノミクス，エルエルシー Ｐａｒａｄｉｇｍ薬剤反応ネットワーク
WO2015003000A1 (en) * 2013-07-01 2015-01-08 Counterpoint Health Solutions, Inc. Systems biology approach to therapy
WO2015181284A1 (en) * 2014-05-28 2015-12-03 Vito Nv A method for the relative quantification of chemical compounds contained in a mixture of different biological samples
KR102662004B1 (ko) * 2014-09-11 2024-04-29 버그 엘엘씨 환자 데이터에 기반한 헬스케어 진단 및 치료를 위한 베이지안 인과 관계 네트워크 모델
SG11201702490PA (en) 2014-10-10 2017-04-27 Akira Matsumori Method for detecting cardiac failure patient, method for discrimination of cardiac disease, test reagent for cardiac failure, test kit for cardiac failure, device for detecting cardiac failure, and program for detecting cardiac failure
SG11201704660YA (en) 2014-12-08 2017-07-28 Berg Llc Use of markers including filamin a in the diagnosis and treatment of prostate cancer
US10253355B2 (en) 2015-03-30 2019-04-09 Accelerate Diagnostics, Inc. Instrument and system for rapid microorganism identification and antimicrobial agent susceptibility testing
EP3278115A2 (en) 2015-03-30 2018-02-07 Accelerate Diagnostics, Inc. Instrument and system for rapid microorganism identification and antimicrobial agent susceptibility testing
CN106250717B (zh) * 2015-06-04 2019-03-12 徐勇 急性髓性白血病的miRNA与转录因子的系统及其构建方法和应用
KR101881398B1 (ko) * 2016-04-07 2018-07-24 한국과학기술원 생물학적 시스템 정보 처리 장치 및 방법
US20200185063A1 (en) 2016-06-05 2020-06-11 Berg Llc Systems and methods for patient stratification and identification of potential biomarkers
US10282588B2 (en) * 2016-06-09 2019-05-07 Siemens Healthcare Gmbh Image-based tumor phenotyping with machine learning from synthetic data
CA3043709A1 (en) 2016-11-14 2018-05-17 Berg Llc Methods for treating parkinson's disease
WO2018094204A1 (en) * 2016-11-17 2018-05-24 Arivale, Inc. Determining relationships between risks for biological conditions and dynamic analytes
CA3060364A1 (en) * 2017-05-12 2018-11-15 Laboratory Corporation Of America Holdings Compositions and methods for detection of diseases related to exposure to inhaled carcinogens
CN109086570B (zh) * 2018-06-29 2020-09-04 迈凯基因科技有限公司 一种多数据库依次交互方法及装置
US20210233640A1 (en) * 2018-06-29 2021-07-29 The Jackson Laboratory Methods and apparatus for identifying alternative splicing events
US11041847B1 (en) 2019-01-25 2021-06-22 Ixcela, Inc. Detection and modification of gut microbial population
JP2022523564A (ja) 2019-03-04 2022-04-25 アイオーカレンツ， インコーポレイテッド 機械学習を使用するデータ圧縮および通信
WO2021005729A1 (ja) * 2019-07-09 2021-01-14 株式会社島津製作所 ｉＰＳ細胞の分化効率予測モデルの構築方法及びｉＰＳ細胞の分化効率予測方法
EP4029019A4 (en) * 2019-09-11 2023-10-11 Recursion Pharmaceuticals, Inc. SYSTEMS AND METHODS FOR PAIRWISE INFERENCE OF DRUG-GENE INTERACTION NETWORKS
CN112151109B (zh) * 2020-09-09 2023-08-25 中国科学院大连化学物理研究所 用于评价生物分子交联质谱鉴定随机性的半监督学习方法
CN112466403B (zh) * 2020-12-31 2022-06-14 广州基迪奥生物科技有限公司 一种细胞通讯分析方法及系统
KR102556312B1 (ko) 2021-04-12 2023-07-19 서울대학교병원 세뇨관 배양부 및 간질 배양부를 포함하는 신장 모사 장기 칩
WO2023102204A1 (en) * 2021-12-03 2023-06-08 The Trustees Of Indiana University Biomarker for type 1 diabetes
CN116046877B (zh) * 2023-04-03 2024-03-15 深圳先进技术研究院 疾病模型代谢分析方法、包埋模具及喷涂装置

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
WO1990002809A1 (en) 1988-09-02 1990-03-22 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
CA2109602C (en) 1990-07-10 2002-10-01 Gregory P. Winter Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0546073B1 (en) 1990-08-29 1997-09-10 GenPharm International, Inc. production and use of transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0564531B1 (en) 1990-12-03 1998-03-25 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
JP4146512B2 (ja) 1991-03-01 2008-09-10 ダイアックス コープ． 小型タンパク質
DK1471142T3 (da) 1991-04-10 2009-03-09 Scripps Research Inst Heterodimere receptor-biblioteker under anvendelse af fagemider
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5621083A (en) 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
EP0916396B1 (en) 1991-11-22 2005-04-13 Affymetrix, Inc. (a Delaware Corporation) Combinatorial strategies for polymer synthesis
US6025165A (en) 1991-11-25 2000-02-15 Enzon, Inc. Methods for producing multivalent antigen-binding proteins
DE69326967T2 (de) 1992-01-17 2000-06-15 Lakowicz Joseph R Phasenmodulationsenergieübertragungsfluoroimmunassay
US5918200A (en) 1992-08-31 1999-06-29 Yamatake-Honeywell Co., Ltd. State estimating apparatus
CA2153387A1 (en) 1993-01-07 1994-07-21 Hubert Koester Dna sequencing by mass spectrometry
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
CA2158642A1 (en) 1993-03-19 1994-09-29 Hubert Koster Dna sequencing by mass spectrometry via exonuclease degradation
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM
DE69829402T2 (de) 1997-10-31 2006-04-13 Affymetrix, Inc. (a Delaware Corp.), Santa Clara Expressionsprofile in adulten und fötalen organen
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
EP1077724A2 (en) * 1998-04-17 2001-02-28 The University Of Vermont Methods and products related to metabolic interactions in disease
US6763307B2 (en) 2000-03-06 2004-07-13 Bioseek, Inc. Patient classification
EP1380001A2 (en) 2001-03-13 2004-01-14 Ashni Naturaceuticals, Inc. Method for association of genomic and proteomic pathways associated with physiological or pathophysiological processes
US8000949B2 (en) 2001-06-18 2011-08-16 Genego, Inc. Methods for identification of novel protein drug targets and biomarkers utilizing functional networks
US7393656B2 (en) 2001-07-10 2008-07-01 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for risk stratification
US7415359B2 (en) 2001-11-02 2008-08-19 Gene Network Sciences, Inc. Methods and systems for the identification of components of mammalian biochemical networks as targets for therapeutic agents
WO2003099320A1 (en) 2002-05-24 2003-12-04 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
ATE398808T1 (de) 2002-08-29 2008-07-15 Gene Network Sciences Inc Systeme und verfahren zum schliessen auf biologische netzwerke
CN1714371A (zh) * 2002-11-19 2005-12-28 Gni美国公司 根据时间序列基因表达数据的基因网络的非线性模拟
JP4288345B2 (ja) 2003-06-19 2009-07-01 独立行政法人産業技術総合研究所 新規てんかんモデル動物
EP1512970A1 (en) * 2003-09-05 2005-03-09 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Method for determining the impact of a multicomponent mixture on the biological profile of a disease
JPWO2005035780A1 (ja) * 2003-10-14 2006-12-21 株式会社セルフリーサイエンス 指標物質の新規スクリーニング方法
WO2005107412A2 (en) * 2004-04-30 2005-11-17 Rosetta Inpharmatics Llc Systems and methods for reconstruction gene networks in segregating populations
EP1607898A3 (en) 2004-05-18 2006-03-29 Neal E. Solomon A bioinformatics system for functional proteomics modelling
US20100316629A1 (en) 2004-09-01 2010-12-16 Shaughnessy Jr John D Use of gene expression profiling to predict survival in cancer patient
AU2006206159A1 (en) * 2005-01-24 2006-07-27 Massachusetts Institute Of Technology Method for modeling cell signaling systems by means of bayesian networks
EP1866818A1 (en) * 2005-03-31 2007-12-19 Koninklijke Philips Electronics N.V. System and method for collecting evidence pertaining to relationships between biomolecules and diseases
EP1887351A4 (en) 2005-05-31 2009-04-08 Jcl Bioassay Corp SCREENING METHOD FOR SPECIFIC PROTEIN IN DETAILED PROTEOME ANALYSIS
US20090035312A1 (en) 2005-09-30 2009-02-05 Universiteit Maastricht Tumor angiogenesis associated genes and a method for their identification
WO2007086515A1 (ja) * 2006-01-27 2007-08-02 Takeda Pharmaceutical Company Limited 遺伝子発現解析ツール
US8571803B2 (en) * 2006-11-15 2013-10-29 Gene Network Sciences, Inc. Systems and methods for modeling and analyzing networks
CN101105841B (zh) * 2007-02-12 2011-06-15 浙江大学 由大规模基因芯片表达谱数据构建基因调控亚网络的方法
US8140270B2 (en) * 2007-03-22 2012-03-20 National Center For Genome Resources Methods and systems for medical sequencing analysis
CA2684665A1 (en) * 2007-05-16 2009-02-12 Edsa Micro Corporation Real-time predictive systems for intelligent energy monitoring and management of electrical power networks
JP2009050171A (ja) 2007-08-23 2009-03-12 Toyobo Co Ltd 表面プラズモン共鳴による基板上におけるリン酸化の検出方法
US7895146B2 (en) * 2007-12-03 2011-02-22 Microsoft Corporation Time modulated generative probabilistic models for automated causal discovery that monitors times of packets
EP3369827B1 (en) * 2008-03-12 2020-12-23 The Rockefeller University Methods and compositions for translational profiling and molecular phenotyping
EA022884B1 (ru) 2008-08-15 2016-03-31 Мерримак Фармасьютикалз, Инк. СПОСОБ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ С ИСПОЛЬЗОВАНИЕМ АНТИ-ErbB3 АНТИТЕЛА
CA2761717A1 (en) 2009-05-11 2010-11-18 Berg Biosystems, Llc Methods for treatment of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
JP5822309B2 (ja) 2010-03-31 2015-11-24 国立大学法人 熊本大学 統合プロテオーム解析用データ群の生成方法ならびに同生成方法にて生成した統合プロテオーム解析用データ群を用いる統合プロテオーム解析方法、およびそれを用いた原因物質同定方法
AU2012376214B2 (en) * 2012-04-02 2019-02-14 Berg Llc Interrogatory cell-based assays and uses thereof
WO2015003000A1 (en) * 2013-07-01 2015-01-08 Counterpoint Health Solutions, Inc. Systems biology approach to therapy

Also Published As

Publication number Publication date
EP2680925A4 (en) 2014-12-31
PE20180776A1 (es) 2018-05-07
CN103501859A (zh) 2014-01-08
IL257824A (en) 2018-04-30
SG10201601224WA (en) 2016-03-30
JP2017148046A (ja) 2017-08-31
WO2012119129A1 (en) 2012-09-07
AU2017202977B2 (en) 2019-09-19
PE20140627A1 (es) 2014-05-30
MY181093A (en) 2020-12-17
CA2828972A1 (en) 2012-09-07
MY164530A (en) 2017-12-29
CN107273712A (zh) 2017-10-20
CN103501859B (zh) 2017-08-25
CN107273712B (zh) 2021-12-03
US20180260515A1 (en) 2018-09-13
PH12017502072A1 (en) 2019-01-14
SG193006A1 (en) 2013-10-30
BR112013022208A2 (pt) 2022-03-08
US20120258874A1 (en) 2012-10-11
EP2680925A1 (en) 2014-01-08
CL2013002526A1 (es) 2014-04-25
EA201391245A1 (ru) 2014-05-30
ES2777894T3 (es) 2020-08-06
AU2012223136B2 (en) 2017-05-25
PH12017502073A1 (en) 2019-01-14
MX358408B (es) 2018-08-20
NZ712105A (en) 2017-05-26
KR102071081B1 (ko) 2020-01-29
US11456054B2 (en) 2022-09-27
IL228096A0 (en) 2013-09-30
KR20140013006A (ko) 2014-02-04
IL228096B (en) 2018-03-29
CA2828972C (en) 2021-09-07
US9886545B2 (en) 2018-02-06
ZA201306453B (en) 2021-05-26
MX2013010068A (es) 2013-11-01
JP6105491B2 (ja) 2017-03-29
NZ614891A (en) 2016-01-29
CO6801640A2 (es) 2013-11-29
US20240062844A1 (en) 2024-02-22
EP2680925B1 (en) 2019-11-20
AU2017202977A1 (en) 2017-05-25
AU2012223136A1 (en) 2013-09-19
JP2014512520A (ja) 2014-05-22

Similar Documents

Publication Publication Date Title
CL2020002805A1 (es) Método para identificar un modulador de un sistema biológico; método para identificar un modulador de un proceso de enfermedad (divisional 201302526)
CL2016003324A1 (es) Construcciones de anticuerpos multiespecificos.
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
BR112013011083A2 (pt) processo e sistema para treinamento pessoal automatizado
BR112015030918A2 (pt) método para produção de células progenitoras renais, e fármacos contendo células progenitoras renais
UY32509A (es) Sistema y método para identificar árboles mediante el uso de modelos lidar de árboles
BR112013025777A2 (pt) imidazopiridazinas como inibidores da quinase akt
PE20151652A1 (es) Proceso e intermedios para preparar un medicamento
BR112015021189A2 (pt) métodos de banco de células de alta densidade
AR090319A1 (es) Biorrefineria integrada
AR081151A1 (es) Metodo para producir bacterias pertenecientes al genero bifidobacterium
AR079704A1 (es) Anticuerpos anti-bv8 y sus usos
CL2016000746A1 (es) Un método para producir un l-aminoácido usando una bacteria de la familia de las enterobacteriaceae teniendo atenuada la expresión de un gen que codifica un transportador de fosfato
CU20170108A7 (es) Composición ácida a base de leonardita y aminoácidos
IN2012DE00401A (es)
CR20140444A (es) Un sistema y un método para la producción integrada de etanol de primera y segunda generación, y uso de puntos de integración para dicha producción
BR112014006911A2 (pt) aditivos de perda de fluido e métodos de produção e uso dos mesmos
EA201791659A1 (ru) Компьютеризированный способ создания модели процесса ферментации
BR112016023624A2 (pt) proteínas de antiporte prótons/ açúcar tonoplásticas e uso do mesmo para o aumento da concentração de sacarose de um órgão de plantas para armazenamento de sacarose
BR112016006383A8 (pt) métodos para extração de uma proteína solúvel, produção de uma composição e produção de um suporte sólido ou semissólido
BR112014027223A2 (pt) métodos e sistemas para fornecer informações de atualização de descrição de dispositivo de um instrumento de campo
AR085824A1 (es) Anticuerpo anti-receptor il-3 humano
SG195170A1 (en) Methods of treating or preventing rheumatic disease
CO7101191A2 (es) Método de preparación de antobiótico novedoso y sistema de plataforma con base en el mismo
BR112014005383C8 (pt) complexo bis-iminopiridina de lantanídeos, sistema catalítico compreendendo o dito complexo bis-iminopiridina e processo para a (co)polimerização de dienos conjugados